Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors

(American Association for Cancer Research) A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.

https://www.eurekalert.org/pub_releases/2019-03/aafc-mct032519.php

Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news